Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer

Clinical Chemistry

Volumn 54, Issue 3, 2008, Pages 582-589

  Fredriksson, Simon ^a,d   Horecka, Joe ^a   Brustugun, Odd Terje ^a,e   Schlingemann, Joerg ^c   Koong, Albert C ^b   Tibshirani, Rob ^b   Davis, Ronald W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d OLINK BIOSCIENCE   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOXYPEPTIDASE A; CARCINOEMBRYONIC ANTIGEN; CHITINASE; CONNECTIVE TISSUE GROWTH FACTOR; DISINTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; GALECTIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 7; MACROPHAGE MIGRATION INHIBITION FACTOR; MESOTHELIN; METALLOPROTEINASE; MONOCLONAL ANTIBODY; OSTEOPONTIN; POLYCLONAL ANTIBODY; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SOMATOMEDIN B; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; AMPLICON; ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MOLECULAR PROBE; MULTIPLEXED PROXIMITY LIGATION ASSAY; OVARY CANCER; PANCREAS CANCER; PILOT STUDY; PLASMA; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 40449135660     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.093195     Document Type: Article

References (36)

1. Fredriksson S, Gullberg M, Jarvius J, Olsson C, Pietras K, Gustafsdottir SM, et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002;20:473-7.
2. Gullberg M, Gustafsdottir SM, Schallmeiner E, Jarvius J, Bjarnegard M, Betsholtz C, et al. Cytokine detection by antibody-based proximity ligation. Proc Natl Acad Sci U S A 2004;101:8420-4.
3. Fredriksson S, Dixon W, Ji H, Koong AC, Mindrinos M, Davis RW. Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat Methods 2007;4:327-9.
4. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
5. Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res 2007;67:186-93.
6. Matsugi S, Hamada T, Shioi N, Tanaka T, Kumada T, Satomura S. Serum carboxypeptidase A activity as a biomarker for early-stage pancreatic carcinoma. Clin Chim Acta 2007;378:147-53.
7. Genomics Institute of the Novartis Research Foundation http://symatlas.gnf.org/SymAtlas/ (accessed December 2006).
8. Fioretti P, Gadducci A, Ferdeghini M, Bartolini T, Scatena P, Facchini V, Bianchi R. Combined evaluation of some tumor associated antigens in the monitoring of integrated surgical and chemotherapeutic treatment of epithelial ovarian cancer. Eur J Gynaecol Oncol 1986;7:200-5.
9. Zeisler H, Tempfer C, Joura EA, Sliutz G, Koelbl H, Wagner O, Kainz C. Serum interleukin 1 in ovarian cancer patients. Eur J Cancer 1998;34:931-3.
10. Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, et al. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer 2006;107:2337-45.
11. Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, Anderson GL, Urban N. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 2006;12:2117-24.
12. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
13. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50.
14. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006;3:995-1000.
15. Schallmeiner E, Oksanen E, Ericsson O, Spangberg L, Eriksson S, Stenman UH, et al. Sensitive protein detection via triple-binder proximity ligation assays. Nat Methods 2007;4:135-7.
16. Niu W, Jiang N, Hu Y. Detection of proteins based on amino acid sequences by multiple aptamers against tripeptides. Anal Biochem 2007;362:126-35.
17. Landegren U, Fredriksson S. Methods and kits for proximity probing. 2000 US2002064779 and WO/2001/061037.
18. Ohkura H, Sakawaki T. Comparison of three new tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2. Gan No Rinsho 1985;31:583-8.
19. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-9.
20. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000;47:1750-2.
21. Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, Leach SD, et al. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 2005;1:779-87.
22. Birk D, Gansauge F, Gansauge S, Formentini A, Lucht A, Beger HG. Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR): clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 1999;25:89-96.
23. Okada N, Ohshio G, Yamaki K, Imamura T, Imamura M. Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. Oncology 1995;52:392-6.
24. Hoog A, Kjellman M, Nordqvist AC, Hoog CM, Juhlin C, Falkmer S, et al. Insulin-like growth factor-II in endocrine pancreatic tumours: immunohistochemical, biochemical and in situ hybridization findings. APMIS 2001;109:127-40.
25. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
26. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-91.
27. Kobayashi A, Yamaguchi T, Ishihara T, Ohshima T, Baba T, Shirai Y, et al. Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival. Pancreas 2005;31:74-8.
28. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15.
29. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-9.
30. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, et al. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:306-18.
31. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 2004;35:1014-21.
32. Yazici H, Dolapcioglu K, Buyru F, Dalay N. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. Cancer Invest 2000;18:110-4.
33. Abendstein B, Daxenbichler G, Windbichler G, Zeimet AG, Geurts A, Sweep F, Marth C. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res 2000;20:569-72.
34. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005;102:7677-82.
35. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005;96:516-9.
36. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7.